文献速递消化道肿瘤与早癌

不可切除转移性结直肠癌一线治疗中循环肿瘤DNA的基因组时间异质性

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
PubMed 文献 · Gut · 2021-09-06

这项前瞻性队列研究(NCT04228614)纳入171例接受一线治疗的不可切除转移性结直肠癌患者,纵向采集血样及部分肿瘤组织。结果显示基线组织与血浆RAS/BRAF一致性为81.0%(51/63);一线治疗后42.6%(26/61)RAS突变患者和50.0%(5/10)BRAF突变患者出现血浆清除,而新发RAS/BRAF突变分别仅3.6%(3/84)和0.7%(1/135)。血浆RAS/BRAF清除者预后与持续野生型相似,显著优于持续突变者;新发突变者预后与持续突变者相似,差于持续野生型。

要点

  • 基线组织与血浆RAS/BRAF一致性为81.0%(51/63)。
  • 一线治疗后RAS清除率42.6%(26/61),BRAF清除率50.0%(5/10)。
  • 血浆RAS/BRAF状态转变可显著改变生存结局,需临床关注。

核心结论

  • 转移性结直肠癌相关体细胞变异在ctDNA中呈现时间异质性,血浆RAS/BRAF突变状态转变可导致生存结局大幅改变,临床应特别关注。

研究设计与样本

  • 前瞻性队列研究(NCT04228614),纳入171例接受一线治疗的不可切除转移性结直肠癌患者,基线及序贯采集血样,部分患者配对肿瘤样本。

主要发现

  • 63例配对基线组织与血浆RAS/BRAF一致性为81.0%(51/63)。
  • 一线治疗后(基线与末次液体活检中位时间4.67个月),42.6%(26/61)RAS突变患者和50.0%(5/10)BRAF突变患者出现血浆清除。
  • 新发RAS突变仅3.6%(3/84),新发BRAF突变仅0.7%(1/135)。
  • 血浆RAS/BRAF清除者的PFS和OS与持续野生型相似,显著优于持续突变者。
  • 新发RAS/BRAF突变者预后与持续突变者相似,PFS和OS短于持续野生型。

临床怎么用

  • 临床管理不可切除转移性结直肠癌时,应关注血浆RAS/BRAF突变状态的时间变化,而非仅依赖基线检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Circulating tumour DNA (ctDNA) sequencing is increasingly used in the clinical management of patients with colorectal cancer. However, the genomic heterogeneity in ctDNA during treatments and its impact on clinical outcomes remain largely unknown. DESIGN: We conducted a prospective cohort study (NCT04228614) of 171 patients with unresectable metastatic colorectal cancer (mCRC) who underwent first-line treatment and prospectively collected blood samples with or without tumour samples from patients at baseline and sequentially until disease progression or last follow-up. RESULTS: The RAS/BRAF alterations in paired baseline tissue and plasma samples from 63 patients displayed a favourable concordance (81.0%, 51/63). After a period of first-line treatment (median time between baseline and last liquid biopsy, 4.67 months), 42.6% (26/61) of RAS-mutant patients showed RAS clearance and 50.0% (5/10) of BRAF-mutant patients showed BRAF clearance, while 3.6% (3/84) and 0.7% (1/135) of patients showed new RAS or BRAF mutations in ctDNA. Patients with plasma RAS/BRAF clearance showed similar progression-free survival (PFS) and overall survival (OS) with patients who remained RAS/BRAF wild-type, while much better outcomes than those who remained RAS/BRAF mutant. Patients who gained new RAS/BRAF mutations showed similar prognosis as those who maintained RAS/BRAF mutations, and shorter PFS and OS than those who remained RAS/BRAF wild-type. CONCLUSION: This prospective, serial and large-scale ctDNA profiling study reveals the temporal heterogeneity of mCRC-related somatic variants, which should be given special attention in clinical practice, as evidenced by the finding that the shift in plasma RAS/BRAF mutational status can yield a drastic change in survival outcomes.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang F, Huang YS, Wu HX, et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2021. PMID: 34489309. doi:10.1136/gutjnl-2021-324852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。